Magnesium in Liver Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01894867|
Recruitment Status : Unknown
Verified June 2013 by Meir Medical Center.
Recruitment status was: Not yet recruiting
First Posted : July 10, 2013
Last Update Posted : July 12, 2013
Several studies have shown in patients magnesium deficiency with liver cirrhosis.
Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium.
We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.
|Condition or disease||Intervention/treatment||Phase|
|LIVER CIRRHOSIS||Dietary Supplement: magnesium Dietary Supplement: Placebo||Phase 4|
Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions.
There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem.
Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis.
There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).
The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Magnesium Deficiency in Cirrhotic Patients|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||April 2014|
will get magnesium for 6 weeks
Dietary Supplement: magnesium
supply magnesium oxide for 6 weeks
Other Name: magnesium oxide
Placebo Comparator: placebo
will get placebo for 6 weeks
Dietary Supplement: Placebo
- change in minimal hepatic encephalopathy [ Time Frame: 6 weeks ]
- change in muscle weakness [ Time Frame: 6 weeks after intervention ]
- chang in other cirrhosis parameters [ Time Frame: 6 weeks after intervention ]change in liver function test (AST ALT GPT GGT ALBUMIN INR) change in magnesium level
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01894867
|Contact: keren cohen, MDemail@example.com|
|Contact: yona kitay, MDfirstname.lastname@example.org|
|liver outpatients clinic, Meir medical center||Not yet recruiting|
|Kfar Saba, Israel|
|Contact: keren cohen, MD 97297471560 email@example.com|
|Principal Investigator: keren cohen, MD|
|Sub-Investigator: YONA KITAY, MD|
|Principal Investigator:||keren cohen, MD||Meir Medical Center|